Pet therapeutics company Aratana Therapeutics Inc (Nasdaq:PETX) reported on Monday the receipt of approval from the US Food and Drug Administration's Center for Veterinary Medicine (CVM) for an additional vial size in 10 ml for NOCITA (bupivacaine liposome injectable suspension) for the management of pain in dogs and cats.
Currently, NOCITA is available in a 20 ml vial size only and the NOCITA in 10 ml vial is expected to be launched commercially by the autumn this year, added the company.
According to the company, NOCITA is US FDA-approved for single-dose infiltration into the surgical site to provide local post-operative analgesia for cranial cruciate ligament surgery in dogs and as a peripheral nerve block to provide regional post-operative analgesia following owner-elected onychectomy in cats.
The company said NOCITA (bupivacaine liposome injectable suspension) is for local infiltration injection in dogs as well as used as a peripheral nerve block in cats.
Sanofi receives FDA orphan drug designation for riliprubart in transplant rejection
Hoth Therapeutics reports positive interim results for HT-001 topical therapy
Breckenridge Pharmaceutical's generic for Ablysinol granted final FDA approval
Hemab Therapeutics presents bleeding disorder clinical and preclinical data at ISTH 2025 Congress
Cumberland Pharmaceuticals reports ifetroban Phase 2 DMD heart disease trial results
Sarclisa recommended for EU approval in newly diagnosed transplant-eligible multiple myeloma
FDA approves Dupixent as first targeted therapy for rare skin disease bullous pemphigoid